Compare BNTX & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNTX | DGX |
|---|---|---|
| Founded | 2008 | 1967 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2B | 22.6B |
| IPO Year | 2019 | 1996 |
| Metric | BNTX | DGX |
|---|---|---|
| Price | $91.52 | $197.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 13 |
| Target Price | $133.46 | ★ $214.38 |
| AVG Volume (30 Days) | ★ 928.5K | 689.6K |
| Earning Date | 05-05-2026 | 04-21-2026 |
| Dividend Yield | N/A | ★ 1.82% |
| EPS Growth | N/A | ★ 13.78 |
| EPS | N/A | ★ 2.24 |
| Revenue | N/A | ★ $11,035,000,000.00 |
| Revenue This Year | N/A | $7.53 |
| Revenue Next Year | $3.37 | $3.77 |
| P/E Ratio | ★ N/A | $89.44 |
| Revenue Growth | N/A | ★ 11.78 |
| 52 Week Low | $79.81 | $164.65 |
| 52 Week High | $124.00 | $213.50 |
| Indicator | BNTX | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 50.77 | 50.80 |
| Support Level | $90.67 | $190.00 |
| Resistance Level | $95.14 | $201.62 |
| Average True Range (ATR) | 2.61 | 4.47 |
| MACD | 0.46 | 0.28 |
| Stochastic Oscillator | 51.46 | 40.73 |
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.